{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreia52dvltxohymhfdvnyoclhvfzbg4vhbih3ocb6tixspcbd4d3kmq",
    "uri": "at://did:plc:svcthvzunxmjidtlw23zva6n/app.bsky.feed.post/3mhe6vkqlcyq2"
  },
  "path": "/2026/03/18/kelun-biotech-to-present-the-final-os-analysis-of-sacituzumab-tirumotecan-sac-tmt-from-the-optitrop-lung03-study/",
  "publishedAt": "2026-03-18T14:31:00.000Z",
  "site": "https://laotiantimes.com",
  "tags": [
    "Cision PR Newswire"
  ],
  "textContent": "CHENGDU, China, March 18, 2026 /PRNewswire/ — The 2026 European Lung Cancer Congress (ELCC) will be held in Copenhagen, Denmark, from March 25 to 28, 2026 (local time). At this congress, the final OS analysis from the pivotal study (OptiTROP-Lung03) of sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) (佳泰莱®), a TROP2 ADC developed by Sichuan Kelun-Biotech […]",
  "title": "Kelun-Biotech to Present the Final OS Analysis of Sacituzumab Tirumotecan (Sac-TMT) from the OptiTROP-Lung03 Study"
}